Arjo AB's basic earnings per share (Basic EPS) for the
three
months ended in Mar. 2026 was €0.04.
Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was €0.12.
Arjo AB's EPS (Diluted) for the
three
months ended in Mar. 2026 was €0.04.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €0.12.
Arjo AB's EPS without NRI for the
three
months ended in Mar. 2026 was €0.04.
Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 0.15.
During the past 12 months, Arjo AB's average EPS without NRIGrowth Rate was -21.30% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was -2.30% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was -5.10% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 2.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 13 years, Arjo AB's highest 3-Year average EPS without NRI Growth Rate was 26.10% per year. The lowest was -23.10% per year. And the median was -2.90% per year.
Arjo AB (FRA:A39) EPS (Basic) Explanation
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Arjo AB EPS (Basic) Related Terms
Arjo AB EPS (Basic) Historical Data
* Premium members only.
The historical data trend for Arjo AB's EPS (Basic) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.
Arjo AB's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as
EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.12
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arjo AB (FRA:A39) has a EPS (Basic) of €0.12 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Arjo AB and its competitors.
Is Arjo AB's EPS (Basic) too high?
Arjo AB's current EPS (Basic) is €0.12. Overall, Arjo AB has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Arjo AB's EPS (Basic) compare to MCK and COR?
Arjo AB's EPS (Basic) of €0.12 can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Medical Distribution company?
A good EPS (Basic) depends on the Medical Distribution industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Arjo AB and its competitors. Arjo AB's current EPS (Basic) is €0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arjo AB stock overvalued right now?
Based on GuruFocus' analysis, Arjo AB (FRA:A39) is currently considered Significantly Undervalued. The stock's GF Value™ is €3.24, compared to a current price of €2.16 — trading 33.2% below its estimated fair value. The current EPS (Basic) is €0.12. Arjo AB's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Arjo AB (FRA:A39), the current EPS (Basic) is €0.12 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arjo AB (FRA:A39) Overvalued in 2026?
Based on GuruFocus' analysis, Arjo AB stock appears to be undervalued.
The current stock price of €2.16 is trading 33.2% below its estimated GF Value™ of €3.24.
GuruFocus considers Arjo AB to be Significantly Undervalued.
Key valuation signals for FRA:A39:
EPS (Basic): €0.12
GF Value™: €3.24 vs. price of €2.16 (33.2% below fair value)
No single metric tells the full story. See the FRA:A39 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arjo AB is a supplier of medical devices, services, and solutions in Sweden. It serves its services to private and public institutions with acute care and long-term care. The company's offering includes products and solutions for patient handling, hygiene, disinfection, medical beds, therapeutic surfaces, venous thromboembolism (VTE) prevention and diagnostics. The company includes segments: Global Sales, North America, Diagnostics.
72GF Score
Get the complete analysis for FRA:A39
EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:A39 has been successfully added to your 
